Pfizer's Prevenar 20 expands EU label for pediatric streptococcal pneumonia [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Prevenar 20 (20-valent Pneumococcal Conjugate Vaccine) for the active immunisation and protection of infants and children against common pneumococcal diseases. The latest EU approval is based on data from four Phase III studies evaluating the safety and immunogenicity of Prevenar 20 in pediatric patients and is accompanied by a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The vaccine is marketed as Prevnar 20 in the US. Prevenar 20 is a 20-valent pneumococcal conjugate vaccine designed to stave off invasive pneumonia, and acute otitis media caused by 20 different serotypes of Streptococcus pneumoniae . While the vaccine is already approved for use in adults, the latest approval authorises its use in those between the ages of 6 weeks and 18 years. As per the 13 March press announcement, the latest version of the vaccine expands on Pfizer's Prevenar 13 and includes protection against serotypes 8, 10A, 11A, 12F, 15B, 2
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Novo Nordisk reprimanded in U.K. for failing to disclose payments to health care sector [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector [Yahoo! Finance]Yahoo! Finance
- Oncology Nutrition Market is expected to grow at 7.14 % CAGR from 2023 to 2030 - Exactitude Consultancy [Yahoo! Finance]Yahoo! Finance
- Pfizer Inc. (NYSE:PFE) is favoured by institutional owners who hold 68% of the company [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- PFE's page on the SEC website